ANAB Stock: Price, Earnings History and SEC Filings
AnaptysBio, Inc. (ANAB) last traded at $48.28, down 0.74% on the latest session and down 3.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.11 against an analyst estimate of $-0.46, a beat of 76.1%.
$48.28 -0.74%
1 month-3.94%
52-week high$72.36
52-week low$20.18
Volume293,616
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ANAB earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Sep 21, 2026 | $-0.11 | $-0.46 | +76.09% |
| Mar 2026 | May 12, 2026 | $-1.84 | $-0.32 | -475.00% |
| Dec 2025 | Mar 3, 2026 | $1.58 | $0.89 | +77.53% |
| Sep 2025 | Nov 4, 2025 | $0.52 | $-1.06 | +149.06% |
ANAB beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ANAB
SEC filing data is not available right now. You can search for ANAB on SEC EDGAR.
ANAB news
- AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside?Oct 31, 2026 · finance.yahoo.com
- Is AnaptysBio (ANAB) Undervalued Following Jemperli's Early FDA Approval?Oct 30, 2026 · finance.yahoo.com
- Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings GrowthOct 28, 2026 · finance.yahoo.com
- AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?Oct 27, 2026 · finance.yahoo.com
- Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal CancerOct 19, 2026 · finance.yahoo.com
About AnaptysBio, Inc.
AnaptysBio, Inc. (ANAB) is a US-listed public company on Nasdaq.